Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies

The PARP inhibitor olaparib is an approved treatment method for women with BRCA1 and BRCA2 mutation associated cancers. Here the authors show that olaparib can contribute to synthetic viability of cells if PARP1 is inhibited before BRCA2 loss.

Guardado en:
Detalles Bibliográficos
Autores principales: Xia Ding, Arnab Ray Chaudhuri, Elsa Callen, Yan Pang, Kajal Biswas, Kimberly D. Klarmann, Betty K. Martin, Sandra Burkett, Linda Cleveland, Stacey Stauffer, Teresa Sullivan, Aashish Dewan, Hanna Marks, Anthony T. Tubbs, Nancy Wong, Eugen Buehler, Keiko Akagi, Scott E. Martin, Jonathan R. Keller, André Nussenzweig, Shyam K. Sharan
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2016
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/cf505f822a744ac9ab12008610c61b55
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/cf505f822a744ac9ab12008610c61b55

Ejemplares similares